Trial Profile

A Multicenter, Open-label, Phase II Study of AK104 an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cadonilimab (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Paclitaxel
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Adverse reactions
Sponsors Akeso Biopharma

Most Recent Events

23 Apr 2024 Status changed from active, no longer recruiting to completed.
28 Feb 2024 According to Akeso media release, data from the study were presented in the official journal of the American Association for Cancer Research (AACR), Clinical Cancer Research.
28 Feb 2024 Results presented in the Akeso Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com